Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants.

Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, Pencina MJ, Rizzo M, Rysz J, Abdollahi M, Nicholls SJ, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration Group.

Pharmacol Res. 2013 Jun;72:35-44. doi: 10.1016/j.phrs.2013.03.007. Epub 2013 Mar 28.

PMID:
23542730
2.

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 May 31;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2. Review.

PMID:
24880031
3.

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H.

Eur Heart J. 2013 Jun;34(24):1807-17. doi: 10.1093/eurheartj/eht065. Epub 2013 Mar 6. Review.

PMID:
23470492
4.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 Jan 28;(1):CD005019. doi: 10.1002/14651858.CD005019.pub4. Review.

PMID:
24470059
5.

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF.

Ann Intern Med. 2012 Aug 21;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007. Review.

6.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2013 Sep 11;(9):CD004289. doi: 10.1002/14651858.CD004289.pub5. Review.

PMID:
24022428
7.

Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials.

Zhang X, Xiang C, Zhou YH, Jiang A, Qin YY, He J.

BMC Cardiovasc Disord. 2014 Feb 17;14:19. doi: 10.1186/1471-2261-14-19. Review.

8.

Antioxidants for chronic kidney disease.

Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T, Webster AC, Perkovic V.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD008176. doi: 10.1002/14651858.CD008176.pub2. Review.

PMID:
23076940
9.

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007784. doi: 10.1002/14651858.CD007784. Review. Update in: Cochrane Database Syst Rev. 2014;5:CD007784.

PMID:
19370693
10.

A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?

Nikolic D, Banach M, Nikfar S, Salari P, Mikhailidis DP, Toth PP, Abdollahi M, Ray KK, Pencina MJ, Malyszko J, Rysz J, Rizzo M; Lipid and Blood Pressure Meta-Analysis Collaboration Group.

Int J Cardiol. 2013 Oct 15;168(6):5437-47. doi: 10.1016/j.ijcard.2013.08.060. Epub 2013 Aug 28.

PMID:
24016544
11.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004289. doi: 10.1002/14651858.CD004289.pub4. Review.

PMID:
19588351
12.

Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials.

Nikolic D, Nikfar S, Salari P, Rizzo M, Ray KK, Pencina MJ, Mikhailidis DP, Toth PP, Nicholls SJ, Rysz J, Abdollahi M, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration Group.

Curr Med Res Opin. 2013 May;29(5):435-51. doi: 10.1185/03007995.2013.779237. Epub 2013 Mar 11. Review.

PMID:
23427811
13.

Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis.

Major RW, Cheung CK, Gray LJ, Brunskill NJ.

Clin J Am Soc Nephrol. 2015 May 7;10(5):732-9. doi: 10.2215/CJN.07460714. Epub 2015 Apr 1. Review.

14.

Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.

Vrecer M, Turk S, Drinovec J, Mrhar A.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):567-77.

PMID:
14692706
15.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004289. doi: 10.1002/14651858.CD004289.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD004289.

PMID:
19370598
16.

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.

Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM.

Ann Intern Med. 2012 Aug 21;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005. Review.

PMID:
22910936
17.

Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis.

de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E.

Drugs. 2012 Dec 24;72(18):2365-73. doi: 10.2165/11638240-000000000-00000. Review.

PMID:
23186103
18.

Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.

Rysz J, Gluba-Brzózka A, Banach M, Więcek A.

Int Urol Nephrol. 2015 May;47(5):805-13. doi: 10.1007/s11255-015-0937-9. Epub 2015 Mar 11. Review.

PMID:
25758011
19.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD005019. doi: 10.1002/14651858.CD005019.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD005019.

PMID:
19370615
20.

The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis.

Zhang Z, Wu P, Zhang J, Wang S, Zhang G.

Pharmacol Res. 2016 Mar;105:74-83. doi: 10.1016/j.phrs.2016.01.005. Epub 2016 Jan 15. Review.

PMID:
26776964

Supplemental Content

Support Center